ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. has licensed a portfolio of drug candidates targeting human cytomegalovirus (HCMV) from Germany’s AiCuris, a 2006 spin-off from Bayer HealthCare. Merck will pay AiCuris $144 million up front and up to $436 million in potential milestones. It will also cover development costs. Included in the agreement is letermovir, an oral, late-stage antiviral candidate being tested against HCMV infections in transplant recipients. The agreement marks the first development deal emerging from AiCuris’ anti-infective drug R&D programs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X